Buntanetap Shows Fresh Promise as Annovis Unveils New Evidence of Disease Modification in Parkinsons

The story around Annovis Bio has taken an interesting turn this year. The company has released new biomarker findings from its phase three Parkinsons trial and the results suggest its drug buntanetap may be doing far more than easing symptoms. It may be altering the course of the disease itself. The latest data show that Parkinsons patients who also carry Alzheimer type changes in the brain respond especially well to the treatment. These patients often decline more quickly because toxic proteins from two diseases pile on at the same time. In this group buntanetap produced stronger improvements in thinking and appeared to reduce several markers of brain damage including pTau217 total tau and brain derived tau. These are all signals usually linked with Alzheimers disease. The company believes this supports the idea that buntanetap acts upstream by reducing multiple toxic proteins before they can harm nerve cells. This builds on earlier findings from July 2024 when Annovis reported that buntanetap improved movement non motor symptoms and cognition in the same phase three study. People who had lived with Parkinsons for more than three years and those with balance and gait problems showed the clearest gains. The drug also continued to show a strong safety profile. An independent monitoring board found no serious side effects related to treatment and patient drop out rates remained low. Recruitment was unusually fast with more than five hundred people joining within nine months across the United States and Europe. The journey to these results has not been without its complications. The trial started dosing in late 2022 and reached its final patient visits by the end of the following year. Early in 2024 the company announced an unexpected delay. When the team unblinded the data too many blood samples suggested patients had not taken the drug. This raised alarms until it was traced back to a laboratory issue in how the drug was being measured. Once that was resolved the analysis continued as planned. The significance of the new findings lies in the overlap between Parkinsons and Alzheimers. A large number of people with Parkinsons also carry amyloid and tau changes which accelerate cognitive decline. If buntanetap can reduce these toxic proteins as well as those tied to Parkinsons it would place the drug in a rare position. It hints at a treatment capable of slowing underlying damage rather than only masking symptoms. There are still questions. Long term benefits are not yet proven. It is also unclear whether all Parkinsons patients will respond or only those with Alzheimer type pathology. More research will be needed to confirm how broad the effect really is. Even so the momentum is clear. Annovis now has clinical results showing consistent improvements in movement and thinking along with biomarker evidence pointing towards a disease modifying effect. It is an unusual and promising moment in Parkinsons research and the next steps for buntanetap will be watched closely.